within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX16_Venlafaxine;

model Venlafaxine
  extends Pharmacolibrary.Drugs.ATC.N.N06AX16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06AX16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It is an approved medication and is widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Shelton, RC (2019). Serotonin and Norepinephrine Reuptake Inhibitors. <i>Handbook of experimental pharmacology</i> 250 145–180. DOI:<a href=&quot;https://doi.org/10.1007/164_2018_164&quot;>10.1007/164_2018_164</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30838456/&quot;>https://pubmed.ncbi.nlm.nih.gov/30838456</a></p></li><li><p>Amchin, J, et al., &amp; Klockowski, PM (1999). Effect of venlafaxine on the pharmacokinetics of risperidone. <i>Journal of clinical pharmacology</i> 39(3) 297–309. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10073330/&quot;>https://pubmed.ncbi.nlm.nih.gov/10073330</a></p></li><li><p>Ellingrod, VL, &amp; Perry, PJ (1994). Venlafaxine: a heterocyclic antidepressant. <i>American journal of hospital pharmacy</i> 51(24) 3033–3046. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7856622/&quot;>https://pubmed.ncbi.nlm.nih.gov/7856622</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Venlafaxine;
